United Therapeutics Corporation
US ˙ NasdaqGS ˙ US91307C1027

SecurityUTHR / United Therapeutics Corporation
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership530 shares
Latest Disclosed Value $ 152,295
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 1.30% decrease in ownership of UTHR / United Therapeutics Corporation

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 530 shares of United Therapeutics Corporation (US:UTHR) valued at $152,296 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 537 shares of United Therapeutics Corporation. This represents a change in shares of -1.30% during the quarter. The current value of the position is $290,276 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP United Therapeutics EC US91307C1027 530 -7 -1.30 152 -7.88 1.6925
2025-05-29 2025-03-31 NP United Therapeutics EC US91307C1027 537 82 18.02 166 3.13 1.7586
2025-03-03 2024-12-31 NP United Therapeutics EC US91307C1027 455 -122 -21.14 161 -22.33 1.6094
2024-11-29 2024-09-30 NP United Therapeutics EC US91307C1027 577 -54 -8.56 207 2.49 1.8728
2024-08-29 2024-06-30 NP United Therapeutics EC US91307C1027 631 -187 -22.86 201 7.49 1.8325
2024-05-30 2024-03-31 NP United Therapeutics EC US91307C1027 818 39 5.01 188 9.36 1.5936
2024-02-29 2023-12-31 NP United Therapeutics EC US91307C1027 779 17 2.23 171 -0.58 1.4039
2023-11-29 2023-09-30 NP United Therapeutics EC US91307C1027 762 -170 -18.24 172 -16.10 1.4902
2023-08-28 2023-06-30 NP United Therapeutics EC US91307C1027 932 -17 -1.79 206 -3.30 1.6236
2023-05-30 2023-03-31 NP United Therapeutics EC US91307C1027 949 -122 -11.39 213 -28.62 1.6098
2023-02-28 2022-12-31 NP United Therapeutics EC US91307C1027 1,071 -25 -2.28 298 29.69 1.8012
2022-11-29 2022-09-30 NP United Therapeutics EC US91307C1027 1,096 38 3.59 229 -8.03 1.6015
2022-08-29 2022-06-30 NP United Therapeutics EC US91307C1027 1,058 -246 -18.87 249 6.87 1.7104
2022-05-26 2022-03-31 NP United Therapeutics EC US91307C1027 1,304 -217 -14.27 234 -28.96 1.3824
2022-02-28 2021-12-31 NP United Therapeutics EC US91307C1027 1,521 178 13.25 329 32.79 1.4523
2021-11-29 2021-09-30 NP United Therapeutics EC US91307C1027 1,343 -145 -9.74 248 -7.14 1.0421
2021-08-27 2021-06-30 NP United Therapeutics EC US91307C1027 1,488 -97 -6.12 267 0.38 1.1181
2021-05-27 2021-03-31 NP United Therapeutics EC US91307C1027 1,585 -307 -16.23 265 -7.67 1.1930
2021-03-01 2020-12-31 NP United Therapeutics EC US91307C1027 1,892 -875 -31.62 287 2.87 1.1696
2020-11-25 2020-09-30 NP United Therapeutics EC US91307C1027 2,767 66 2.44 279 -14.42 1.1664
2020-08-27 2020-06-30 NP United Therapeutics EC US91307C1027 2,701 -183 -6.35 327 19.41 1.3171
2020-06-01 2020-03-31 NP United Therapeutics EC US91307C1027 2,884 -183 -5.97 273 1.11 1.6739
2020-03-02 2019-12-31 NP United Therapeutics EC US91307C1027 3,067 162 5.58 270 16.88 1.2504
2019-11-27 2019-09-30 NP United Therapeutics EC US91307C1027 2,905 2,905 232 1.2290
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.